人のウォール街のアナリストによると、Bio Green Med Solution Incの収益見積もりは$から$の範囲です。
Bio Green Med Solution Incの収益品質スコアはどれくらいですか?
Bio Green Med Solution Incの収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Bio Green Med Solution Incはいつ収益を報告しますか?
Bio Green Med Solution Incの次の収益報告は2026-08-10に予定されています
Bio Green Med Solution Incの予想収益はいくらですか?
ウォール街のアナリストによると、Bio Green Med Solution Incの予想収益は$です。
Bio Green Med Solution Incは収益予想を上回りましたか?
Bio Green Med Solution Incの最近の収益は$で、予想を。
主要データ
前終値
$1.1
始値
$1.15
当日レンジ
$1.1 - $1.15
52週レンジ
$0.7303 - $100.8
取引高
200
平均取引高
100.2K
配当利回り
1.14%
1株当たり利益(TTM)
-1.86
時価総額
$6.0M
BGMSPとは何ですか?
Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.